Antibe Therapeutics (ATE) Insider Trading & Ownership Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsEarningsInsider Trades Antibe Therapeutics (TSE:ATE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.94%Number OfInsiders Buying(Last 12 Months)2Amount OfInsider Buying(Last 12 Months)C$19,600.00Number OfInsiders Selling(Last 12 Months)0 Get ATE Insider Trade Alerts Want to know when executives and insiders are buying or selling Antibe Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ATE Insider Buying and Selling by Quarter Antibe Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/7/2024Daniel Marcel LegaultDirectorBuy20,000C$0.50C$10,000.003/6/2024Joseph StaufferSenior OfficerBuy24,000C$0.40C$9,600.00 (Data available from 1/1/2013 forward) ATE Insider Trading Activity - Frequently Asked Questions Who is on Antibe Therapeutics's Insider Roster? The list of insiders at Antibe Therapeutics includes Daniel Marcel Legault, John Lawrence Wallace, Joseph Stauffer, and Scott Wilson Curtis. Learn more on insiders at ATE. What percentage of Antibe Therapeutics stock is owned by insiders? 7.94% of Antibe Therapeutics stock is owned by insiders. Learn more on ATE's insider holdings. Which Antibe Therapeutics insiders have been buying company stock? The following insiders have purchased ATE shares in the last 24 months: Daniel Marcel Legault (C$10,000.00), and Joseph Stauffer (C$9,600.00). How much insider buying is happening at Antibe Therapeutics? Insiders have purchased a total of 44,000 ATE shares in the last 24 months for a total of C$19,600.00 bought. Antibe Therapeutics Key ExecutivesMr. Daniel Marcel Legault J.D. (Age 66)L.L.B., President, CEO, Secretary & Director Compensation: $744.67kMr. Alain Wilson M.B.A.MBA, Chief Financial OfficerMr. Scott Curtis C.F.A.M.Eng, Chief Operating OfficerDr. David James Vaughan Ph.D. (Age 74)Chief Development Officer Compensation: $406.58kDr. Joseph Stauffer D.O. (Age 58)M.B.A., Chief Medical Officer Compensation: $1.11MDr. Ana StegicExecutive Director of Clinical OperationsMs. Christina Cameron B.B.A.Vice President of Investor RelationsMr. Philip SternVice President of Communications More Insider Trading Tools from MarketBeat Related Companies Microbix Biosystems Insider Trades Hemostemix Insider Trades Resverlogix Insider Trades Kane Biotech Insider Trades Innovotech Insider Trades Quest PharmaTech Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Strong Capital Returns and Insider Buying SignalsZymeworks in Focus for Insider Activity: Catalysts AheadInsiders Are Loading Up: 3 Key Stock Picks for InvestorsInsiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop Buying This page (TSE:ATE) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
